Loven et al. (2013) investigated the mechanisms involved in the selective inhibition of MYC oncogenes in MM caused by inhibition of transcriptional coactivator BRD4. They found that treatment of MM tumor cells with the BET domain inhibitor, JQ1, resulted in preferential loss of BRD4 in MYC-SEs and subsequent transcriptional extension defects, which preferentially affected SE-associated genes such as MYC. This also consequently inhibited the progression of MM. The possible functional mechanism of SEs in MM is shown in Figure 2. This evidence concerns the gene MYC and neoplasm.